Cooper Co stock analysis
Cooper Co (CP60) Stock Price & Analysis
CP60 Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 10.00B
- Enterprise Value
- CHF 16.38B
- Total Cash (Recent Filing)
- CHF 154.70M
- Total Debt (Recent Filing)
- CHF 2.54B
- Price to Earnings (P/E)
- 21.4
- Beta
- N/A
- Next Earnings
- Dec 03, 2026 (Est.)
- EPS Estimate
- 0.9
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Strong top-line expansion combined with a high gross margin indicates meaningful demand for the company’s medical device portfolio. If sustained, this supports reinvestment in innovation, commercial capabilities and capacity while providing a durable base for future earnings growth.
Fertility Market Position
Broad-based fertility demand and reported market share gains strengthen CooperSurgical’s position in an expanding care market. Clinic wins, genomics adoption and recurring service relationships can deepen customer ties and support more durable growth than a single product launch.
Conservative Leverage
Moderate and improving leverage gives Cooper flexibility to fund research, commercial investment and strategic initiatives without relying heavily on additional borrowing. The stronger equity base also improves resilience if operating conditions remain uneven over the coming quarters.
Bears Say
Weak Cash Conversion
The sharp TTM decline in operating and free cash flow weakens earnings quality and reduces internally generated funding for investment or shareholder returns. Cash conversion below net income also makes sustained performance more dependent on reversing the factors behind the deterioration.
Operating Margin Pressure
The large operating-margin contraction shows that revenue growth is not currently translating efficiently into operating profit. Additional commercial spending and foreign-exchange pressure may keep profitability below prior levels until execution investments generate sufficient productivity.
Leadership Transition
A chief executive departure and interim operating structure introduce execution and strategic continuity risk during a period that already includes margin pressure and commercial changes. The board search may ultimately strengthen leadership, but the transition can disrupt priorities over the next several quarters.
Cooper Co News
CP60 FAQ
What is Cooper Co’s market cap?
When is Cooper Co’s upcoming earnings report date?
How were Cooper Co’s earnings last quarter?
Is Cooper Co overvalued?
Does Cooper Co pay dividends?
What is Cooper Co’s EPS estimate?
What happened to Cooper Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cooper Co?
What is the TipRanks Smart Score and how is it calculated?
Cooper Co Stock Smart Score
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White
- Employees
- 15,000
- Website
- www.coopercos.com
- Address
- 6101 Bollinger Canyon Road, San Ramon, CA, 94583, US
Cooper Co (CP60) Earnings & Revenues
CP60 Company Deck
CP60 Earnings Call
Earnings Call SentimentPositive
The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.
View all CH:CP60 earnings summariesCP60 Net sales Breakdown
- 67.05% CooperVision
- 32.95% CooperSurgical















